The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.
Immune-related disorders have been hypothesized as etiological factors in schizophrenia.Minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile.This study was performed as a double-blind, placebocontrolled,randomized evaluation of Second generation antipsychotics(SGA) and minocycline versus SGA and placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
78
variable dose SGA and minocycline,100mg per capsule po(take orally) bid,16 weeks;
variable dose SGA and 100mg per capsule po(take orally) bid,16 weeks;
Department of Psychiatry, The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China
Mean Change from Baseline in the Composite Score From the Cognition Assessment Battery and SANS Total Scores After 16 Weeks of Treatment
The Cognitive Assessment Battery included Making Test (TMT) ,Symbol Coding,Hopkins Verbal Learning Test-Revised ,Mazes,Brief Visuospatial Memory Test-Revised ,Continuous Performance Test-Identical Pairs,Grooved Pegboard Test,Color Trail Test,Stroop Task,Verbal Fluency,Paced Auditory Serial Addition Test and Wisconsin Card Sorting Test SANS=Scale for the Assessment of Negative Symptoms
Time frame: 16 weeks
Mean Change from Baseline in the PANSS and PSP Total Scores after 16 weeks Treatment
Time frame: 16 weeks
Cytokine Measure
Cytokine Measure:IL-1β,IL-6,TNF-α,Nitric Oxide (NO)、S100B
Time frame: 16 weeks
metabolic index
weight,height,insulin and waist circumference,
Time frame: 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.